Constitutive DUSP2 expression enhances lymphoid cell proliferation by activating CDK1 and promotes lymphomagenesis.
Scientists identify a new target in cancer cells that could lead to treatments for blood cancers previously thought difficult to tackle.
DUSP2 is highly expressed in human B- and T-cell malignancies and drives lymphoid proliferation through a non-catalytic structural motif that recruits CDC25 phosphatases to activate CDK1, independent of its enzymatic phosphatase activity. This mechanism identifies the DUSP2 structural interface as a novel therapeutic target for lymphoid malignancies.
What the study was
- Study design
- mechanistic in vitro and transgenic mouse study
- Population
- Human B- and T-cell lymphoma cell lines and transgenic mouse models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cell reports
Why it surfaced
Unexpected oncogenic mechanism for DUSP2 in lymphoid malignancies from Dana-Farber/Harvard/Rajewsky group; therapeutic structural motif target; comprehensive in vitro + in vivo evidence in multiple hematologic cancer types.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.